Industries > Pharma > Asthma and COPD Therapies Market Forecast 2015-2025

Asthma and COPD Therapies Market Forecast 2015-2025

Opportunities for Leading Companies

PUBLISHED: 05 October 2015
PAGES: 309
PRODUCT CODE: PHA0070
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
SKU: PHA0070 Categories: ,

Asthma and COPD Therapies Market Forecast 2015-2025: Opportunities for Leading Companies
What can be expected from the Asthma and COPD Therapies market? Which areas are going to grow at the fastest rates? Visiongain’s brand new report shows you potential revenues to 2025, assessing data, trends, opportunities and prospects there.
 
Our 309-page report provides 260 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. You will see financial results, interviews, trends, opportunities, and revenue predictions. There is much opportunity in this fast moving market.

Forecasts from 2015-2025 and other analyses show you commercial prospects
Besides revenue forecasting to 2025, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT and Porter’s Five Forces analysis) and commercial developments.

See revenue forecasts for the leading submarkets and therapies
How will submarkets perform to 2025? Our study forecasts revenues in the following asthma and COPD therapies submarkets:
• Combination drugs
• Anti-inflammatory drugs
– Corticosteroids
– Anti-Leukotrienes
– Monoclonal antibodies
– Other anti-inflammatories
• Bronchodilator monotherapy
– Short-acting beta2-agonist (SABAs)
– Long-acting beta2-agonist (LABAs)
– Anticholinergics

How will individual therapies perform to 2025? Our study forecasts revenues for 27 therapies including 5 promising pipeline candidates:
• Ventolin
• ProAir
• Proventil
• Xopenex
• Foradil
• Serevent
• Arcapta/Onbrez
• Brovana
• Spiriva
• Atrovent
• Eklira/Tudorza/Bretaris
• Flixotide/Flovent
• Pulmicort
• QVAR
• Asmanex
• Singulair
• Xolair
• Cinquil
• Mepolizumab
• Benralizumab
• Lebrikizumab
• Dupilumab
• Advair/Seretide
• Symbicort
• Combivent
• Dulera
• Breo/Relvar Ellipta

See revenue forecasts for the leading international markets
How will leading national markets perform to 2025? Our study forecasts revenues in national markets including products, including:
• US
• Japan
• EU5
• BRIC
• Mexico

Asthma and COPD Therapies Market Forecast 2015-2025 Opportunities for Leading Companies

Leading companies and potential for market growth
Overall revenue for the Asthma and COPD Therapies market will reach $35.87in 2019, our work forecasts. We predict strong revenue growth through to 2025. An ageing population and increasing incidence of respiratory diseases globally will drive sales to 2025.

Our work analyses the key companies in the market. See Visiongain’s analysis of 7 leading companies, including these:
• GSK
• Boehringer Ingelheim
• AstraZeneca
• Merck
• Novartis
• Roche
• Teva

A company profile gives you the following information where available:
• 10 year revenue forecast for respiratory products with annual growth rates
• Discussion of a company’s activities and outlook
• Analysis of products currently on the market as well as those in the pipeline

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

What issues will affect the Asthma and COPD Therapies industry?
Our new report discusses issues and events affecting the Asthma and COPD Therapies market. You will find discussions, including qualitative analyses:
• Highly diverse market needing strong knowledge of national markets
• Patent expiry challenging major market players
• Emerging areas of therapies with potential to reshape the market

You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.

How the Asthma and COPD Therapies Market Forecast 2015-2025 report helps you
In summary, our 309-page report gives you the following knowledge:
• Revenue forecasts to 2025 for the asthma and COPD therapies market – discover the industry’s prospects, finding promising places for investments and revenues
• Revenue forecasts to 2025 for submarkets and leading therapies in each – discover prospects for leading drugs in the following asthma and COPD submarkets: bronchodilator monotherapy (including SABAs, LABAs and anticholinergics), anti-inflammatory drugs (including corticosteroids, anti-leukotrienes and monoclonal antibodies) and combination drugs
• Revenue forecasts to 2025 for the leading regional markets – US, Japan, EU5, BRIC and Mexico
• Assessment of 7leading companies – analysis of respiratory revenues, products and pipeline
• Discussion of what stimulates and restrains companies and the market
• Prospects for established firms and those seeking to enter the market

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else
With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain’s study is for everybody needing commercial analyses for the Asthma and COPD therapies market and leading companies. You find data, trends and predictions. Please order our report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Asthma and COPD Therapies Market Forecast 2015-2025


Download sample pages

Complete the form below to download your free sample pages for Asthma and COPD Therapies Market Forecast 2015-2025


Latest Pharma news

Visiongain Publishes Checkpoint Inhibitors for Treating Cancer Market Report 2021-2031

We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

29 July 2021

READ

Visiongain Publishes Direct-to-Patient Market Report 2021-2031

Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.

21 July 2021

READ

Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031

Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.

20 July 2021

READ

Visiongain Publishes Pharma Contract Sales Market Report 2021-2031

Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.

14 July 2021

READ

Categories